Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Unless they’re covering me in a cloud of norovirus particles. When the violent expelling of liquid starts somewhere other ...

You can also get norovirus by touching objects or surfaces that are contaminated and then putting your hands in your mouth ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

MassMutual Private Wealth & Trust FSB boosted its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 58.2% in the 4th ...

And unlike the other three illnesses that make up the ongoing “quad-demic”—flu, COVID, and respiratory syncytial virus (RSV)—norovirus has no FDA-approved vaccine. Moderna, a Massachusetts-based ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...